Iui Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Intrauterine insemination (IUI) is a minimally invasive assisted reproductive technology (ART) in which a specially prepared semen sample is placed directly into the uterine cavity through a thin, flexible catheter passed through the cervix. The procedure is timed to coincide with ovulation — either natural or stimulated with oral medications such as clomiphene citrate or injectable gonadotrophins — to maximise the probability of fertilisation. The entire insemination procedure takes only a few minutes and does not require anaesthesia.

IUI works by reducing the distance sperm must travel and bypassing the cervical mucus, which can be a barrier for sperm with poor motility or when cervical mucus is hostile. Prior to insemination, the semen sample is processed in an embryology laboratory using density-gradient centrifugation or swim-up techniques to select the most motile, morphologically normal sperm and remove seminal plasma, dead cells, and prostaglandins. The final prepared sample — typically containing at least 1–5 million motile sperm — is then loaded into an insemination catheter.

Patients undergoing IUI with ovarian stimulation attend the clinic for monitoring ultrasounds and blood hormone tests to track follicle growth. When the lead follicle reaches approximately 18–20 mm in diameter, a trigger injection of human chorionic gonadotrophin (hCG) or a GnRH agonist is administered to induce the final maturation and release of the egg. Insemination is performed 24–36 hours after the trigger. After the procedure, patients may be prescribed a short course of vaginal progesterone to support the luteal phase.

A typical IUI treatment cycle spans two to three weeks from the start of ovarian stimulation to the pregnancy test. Most fertility specialists recommend attempting three to six IUI cycles before reassessing and considering more advanced interventions such as in vitro fertilisation (IVF). IUI is widely offered at fertility clinics across India, Thailand, Malaysia, and Spain at a fraction of the cost charged in the United States or United Kingdom.

IUI is most commonly used for couples with unexplained infertility — where standard investigations have not identified a specific cause — and where sperm parameters are borderline normal. It is a first-line treatment option before advancing to IVF, particularly when the woman has at least one patent (open) fallopian tube and reasonable ovarian reserve.

IUI is also indicated for mild to moderate male factor infertility, including low sperm count (oligospermia), reduced motility (asthenospermia), or abnormal morphology (teratospermia), provided the prepared sample meets the minimum threshold for insemination. It is appropriate for couples where cervical factor infertility prevents natural sperm passage — for example, hostile cervical mucus or prior cervical surgery. Women who are single or in a same-sex relationship using donor sperm, and couples in which the male partner has a retrograde ejaculation or ejaculatory dysfunction, are also common candidates for IUI. In cases of mild endometriosis (Stage I–II) without significant tubal or pelvic adhesions, IUI combined with ovarian stimulation remains a clinically accepted option.

Ideal candidates for IUI are women under 38 years of age with confirmed tubal patency (at least one open fallopian tube verified by hysterosalpingography or laparoscopy), adequate ovarian reserve (antral follicle count and anti-Müllerian hormone within acceptable range), and a normal or near-normal uterine cavity. Male partners should produce a post-wash total motile sperm count of at least 5–10 million for the best outcomes, though clinics vary in their minimum thresholds. Women with regular or inducible ovulation, no severe endometriosis, and no significant pelvic adhesions are the most suitable candidates.

IUI is not appropriate for women with bilateral tubal blockage or severe tubal disease, as successful fertilisation requires at least one functional tube. It is also contraindicated in women with severe diminished ovarian reserve, significant uterine abnormalities (large fibroids distorting the cavity, intrauterine adhesions), or active pelvic infection. Couples in which the male partner has very severe oligospermia (fewer than 1 million total motile sperm on semen analysis) or azoospermia (complete absence of sperm) are generally not suitable for IUI with partner sperm and may need to consider donor sperm, surgical sperm retrieval, or IVF/ICSI instead.

IUI can be performed in a natural (unstimulated) cycle or with mild-to-moderate ovarian stimulation. Natural IUI tracks ovulation with serial ultrasounds and a urine LH surge test, avoiding the risk of multiple pregnancy but yielding lower success rates per cycle (around 5–8%). Stimulated IUI uses oral agents (clomiphene citrate or letrozole) or low-dose injectable gonadotrophins (FSH or hMG) to develop one or two dominant follicles, significantly improving pregnancy rates (10–20% per cycle) while increasing the risk of twin or higher-order conception.

Single versus double insemination protocols have been studied extensively. Some clinics perform two inseminations in the same cycle — one on the day of the LH surge and a second 24 hours later — to broaden the fertilisation window, though meta-analyses have not consistently demonstrated superiority of double IUI over a single well-timed insemination. Donor sperm IUI follows the same protocol and is offered to single women, same-sex female couples, and heterosexual couples with severe male factor or untreatable genetic conditions. Sperm donors are screened extensively for genetic diseases, sexually transmitted infections, and physical characteristics to match recipient preferences. Shared decision-making between the patient and specialist ensures the chosen modality aligns with individual anatomy, comorbidities, risk tolerance, and personal goals. A formal consultation with a board-certified specialist, review of pre-treatment imaging or investigation results, and multidisciplinary team input for complex cases are standard practice before finalising the treatment plan.

IUI is the least invasive form of assisted reproduction and can be completed without sedation or hospitalisation, making it an attractive initial step for couples starting fertility treatment. Pregnancy rates per IUI cycle range from 8–20% depending on the woman's age, the cause of infertility, and whether ovarian stimulation is used. Cumulative success after three cycles of stimulated IUI approaches 30–40% for women under 35 with unexplained or mild male factor infertility, which is comparable to natural conception rates over a similar time period.

For couples who eventually require IVF, attempting IUI first allows fertility specialists to gather valuable information about ovarian response to stimulation and sperm function under near-physiological conditions. IUI has a very low complication profile, causes minimal disruption to daily life, and is significantly less expensive than IVF — making it a cost-effective first step. For single women and same-sex couples using donor sperm, IUI offers a straightforward, non-invasive pathway to conception without the biological and financial demands of IVF.

The most common complication of ovarian stimulation for IUI is multiple pregnancy (twins or triplets), occurring in approximately 15–20% of stimulated IUI cycles. Multiple pregnancies carry significantly elevated risks of preterm birth, low birth weight, gestational diabetes, and maternal complications. Ovarian hyperstimulation syndrome (OHSS) can occur with injectable gonadotrophin stimulation but is generally mild in the low-dose protocols used for IUI, with severe OHSS being rare (less than 1%). Mild OHSS presents as abdominal bloating, nausea, and pelvic discomfort and usually resolves within one to two weeks.

The insemination procedure itself carries a very small risk of uterine cramping during catheter passage, which is usually brief and resolves within hours. There is a rare risk of introducing infection into the uterus or fallopian tubes (endometritis or salpingitis), particularly if strict aseptic technique is not maintained. Ectopic pregnancy — implantation outside the uterus, usually in a fallopian tube — occurs in approximately 1–2% of IUI pregnancies and requires prompt medical or surgical management. Psychological stress from repeated unsuccessful cycles is a recognised consequence that should be supported with counselling.

After the IUI procedure, patients are typically asked to rest in the clinic for 10–15 minutes before returning to normal activities. There are no significant physical restrictions following insemination; most women resume work and light activity on the same day. Vaginal progesterone pessaries or gel may be prescribed to support the luteal phase and are continued until the pregnancy test. A blood or urine pregnancy test (beta-hCG) is performed approximately 14 days after insemination. A positive result is followed by an ultrasound at 6–7 weeks to confirm intrauterine pregnancy and viability.

If the cycle is unsuccessful, the fertility team typically reviews the monitoring data — number of follicles developed, endometrial thickness, sperm preparation parameters — to optimise the protocol for subsequent cycles. Couples who have completed three to four unsuccessful IUI cycles with adequate sperm parameters and confirmed tubal patency should be counselled about escalating to IVF, which offers substantially higher success rates per cycle. Emotional support and psychological counselling are recommended throughout the treatment process, particularly for couples who have experienced multiple failures.

The cost of a single IUI cycle varies considerably depending on the country, clinic, and whether ovarian stimulation medications are included. In the United States, a stimulated IUI cycle including monitoring, sperm preparation, and the insemination procedure typically costs USD 1,500–4,000, not including medication costs (USD 500–2,000 additional for injectable gonadotrophins). In the United Kingdom, NHS funding for IUI has been significantly restricted, and private IUI costs range from GBP 700–1,500 per cycle.

Medical tourism for IUI offers substantial savings. In India, a full stimulated IUI cycle including all clinic visits and medications typically costs USD 300–700. Thailand and Malaysia offer comparable quality at USD 400–900 per cycle. Spain and the Czech Republic, popular European fertility tourism destinations, charge EUR 500–1,000 for a stimulated IUI cycle. These savings — often 60–80% compared to US or UK prices — make IUI accessible to a much wider population. Patients travelling abroad should factor in travel, accommodation, and the need for 2–3 clinic visits across 10–14 days.

The main alternative to IUI for infertile couples is in vitro fertilisation (IVF), which involves ovarian stimulation, egg retrieval, laboratory fertilisation, embryo culture, and transfer. IVF has significantly higher per-cycle success rates (35–50% in women under 35) but is substantially more invasive, more expensive, and carries greater risks of OHSS and multiple pregnancy if multiple embryos are transferred. IVF with intracytoplasmic sperm injection (ICSI) is preferred over IUI when sperm parameters are severely abnormal, as ICSI involves direct injection of a single sperm into the egg.

For couples with unexplained infertility, expectant management (timed intercourse with or without ovulation induction) is a reasonable alternative for younger women with a short duration of infertility before proceeding to IUI. Lifestyle interventions — weight normalisation, smoking cessation, alcohol reduction, and folic acid supplementation — can improve natural conception rates and are recommended alongside any assisted reproductive intervention. For couples whose infertility has a surgically correctable cause (tubal obstruction, hydrosalpinx, uterine septum, or male varicocele), surgical correction prior to IUI or IVF may improve outcomes.